Bid to End Duplicate Drug Research

Representatives from industry and academia worldwide convened to design a working plan that would mitigate the wasteful duplication of research efforts often encountered in drug development circles. The POC (Public/private partnership, Open innovation, Clinical consortium) seeks to make pre-competitive (pre-Phase II) results more freely available and thereby save resources and forestall ill-fated clinical trials.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail